Is antitumour necrosis factor therapy combined with ultraviolet B phototherapy safe?
暂无分享,去创建一个
[1] E. Laffitte,et al. Giant warts in a kidney transplant patient: regression with sirolimus , 2010, The British journal of dermatology.
[2] L. Naldi,et al. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.
[3] M. Lebwohl,et al. Treatments for psoriasis and the risk of malignancy. , 2009, Journal of the American Academy of Dermatology.
[4] K. Hemminki,et al. Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden , 2009, British Journal of Cancer.
[5] H. Kerl,et al. Treatment with 311‐nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept , 2009, The British journal of dermatology.
[6] C. Elmets,et al. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. , 2008, Journal of drugs in dermatology : JDD.
[7] V. Werth,et al. TNF-α production in the skin , 2008, Archives of Dermatological Research.
[8] C. Buckley,et al. Skin cancer in psoriatic arthritis treated with anti-TNF therapy. , 2007, Rheumatology.
[9] F. Wolfe,et al. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. , 2005, The Journal of rheumatology.
[10] L. Dubertret,et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. , 2003, The Journal of investigative dermatology.
[11] R. Stern,et al. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. , 1998, Journal of the National Cancer Institute.